Organ responses among VRD-treated patients at landmark points
| Landmark point . | 6 mo . | 12 mo . | Overall ITT . |
|---|---|---|---|
| Renal responses/progression | (n = 18) | (n = 10) | (n = 18) |
| 3 (17)/3 (17) | 4 (40)/3 (30) | 4 (22)/3 (17) | |
| Cardiac response/progression (NTproBNP criteria) | (n = 18) | (n = 18) | (n = 27) |
| 8 (44)/4 (22) | 11 (61)/1 (6) | 11 (41)/10 (37)* |
| Landmark point . | 6 mo . | 12 mo . | Overall ITT . |
|---|---|---|---|
| Renal responses/progression | (n = 18) | (n = 10) | (n = 18) |
| 3 (17)/3 (17) | 4 (40)/3 (30) | 4 (22)/3 (17) | |
| Cardiac response/progression (NTproBNP criteria) | (n = 18) | (n = 18) | (n = 27) |
| 8 (44)/4 (22) | 11 (61)/1 (6) | 11 (41)/10 (37)* |
Values represent n (%) of patients.
Based on NTproBNP increase sustained after the completion of therapy in 1 patient and early death in the other 9 patients.